Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
Study sponsor: CytoDyn, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-06-05Actual
Enrollment · participants56Actual
Source updated2024-04-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.